Targeted delivery to legumain-expressing cells

Details for Australian Patent Application No. 2004248138 (hide)

Owner The Scripps Research Institute Edgington, T. Liu, C.

Inventors Liu, Cheng; Edgington, Thomas S.

Agent Davies Collison Cave

Pub. Number AU-B-2004248138

PCT Pub. Number WO2004/111192

Priority 60/474,840 29.05.03 US

Filing date 28 May 2004

Wipo publication date 23 December 2004

Acceptance publication date 3 September 2009

International Classifications

A61K 38/16 (2006.01) Medicinal preparations containing peptides - Peptides having more than 20 amino acids

A61K 47/48 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

C07K 5/06 (2006.01) Peptides having up to four amino acids in a fully defined sequence

C07K 5/072 (2006.01) Peptides having up to four amino acids in a fully defined sequence

C07K 5/083 (2006.01) Peptides having up to four amino acids in a fully defined sequence

C07K 5/103 (2006.01) Peptides having up to four amino acids in a fully defined sequence

C07K 7/02 (2006.01) Peptides having 5 to 20 amino acids in a fully defined sequence

C07K 9/00 (2006.01) Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence

G01N 33/574 (2006.01) Investigating or analysing materials by specific methods not covered by groups - for cancer

Event Publications

8 December 2005 PCT application entered the National Phase

  PCT publication WO2004/111192 Priority application(s): WO2004/111192

3 September 2009 Application Accepted

  Published as AU-B-2004248138

17 December 2009 Assignment before Grant

  The Scripps Research Institute; Edgington, Thomas; Liu, Cheng The application has been assigned to The Scripps Research Institute

7 January 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004248140-Gene expression markers for response to EGFR inhibitor drugs

2004248136-Methods and compositions for controlling efficacy of RNA silencing